1. Malavige GN, Fernando N, Ogg G. Pathogenesis of Dengue viral infections. Sri Lankan Journal of Infectious Diseases 2011; 1(1): 2-8 DOI: http://dx.doi.org/10.4038/sljid.v1i1.2987
2. Sellahewa KH. Pathogenesis of Dengue Haemorrhagic Fever and Its Impact on Case Management. ISRN Infectious Diseases 2013; 2013, article ID 571646, 6 pages. https://doi.org/10.5402/2013/571646.
3. Yacoub S, Mongkolsapaya J, Screaton G. Recent advances in understanding dengue [version 1; referees: 3 approved] F1000Research 2016, 5(F1000 Faculty Rev):78 doi:10.12688/f1000research.6233.1
4. Khetarpal N, Khanna I. Dengue Fever: Causes, Complications, and Vaccine Strategies. Journal of Immunology Research 2016, Article ID 6803098, 14 pages. https://doi.org/10.1155/2016/6803098.
5. Bhatt S et al. The global distribution and burden of dengue. Nature. 2013 ;496(7446):504-7. doi: 10.1038/nature12060
6. Gordon A et al. The Nicaraguan pediatric dengue cohort study: incidence of inapparent and symptomatic dengue virus infections, 2004-2010. PLoS Negl Trop Dis. 2013;7(9):e2462. doi: 10.1371/journal.pntd.0002462.
7. Sierra B et al. Secondary heterologous dengue infection risk: Disequilibrium between immune regulation and inflammation?. Cellular Immunology 2010;262 :134–140. https:// doi.org/10.1016 /j.cellimm. 2010.02.005
8. Rothman AL, Medin CL, Friberg H, Currier JR. Immunopathogenesis versus Protection in Dengue Virus Infections. Curr Trop Med Rep2014;1(1): 13-20. DOI 10.1007/s40475-013-0009-0
9. Soo K-M, Khalid B, Ching S-M, Chee H-Y. Meta-Analysis of Dengue Severity during Infection by Different Dengue Virus Serotypes in Primary and Secondary Infections. PLoS ONE 2016; 11(5): e0154760. doi:10.1371/journal.pone.0154760.
10. Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev. 2009 Oct;22(4):564-81. doi: 10.1128/CMR.00035-09.
11. Friberg H et al. Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans. Scientific reports 2011.1(): 51. doi:10.1038/srep00051.
12. Thomas SJ, Rohtman AL. Dengue virus infection: pathogenesis. UpToDate [Online]. Availbale in URL: https://www. uptodate.com /contents/dengue-virus-infection-pathogenesis
13. Katzelnick LC et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358(6365):929-932. doi: 10.1126/science.aan6836.
14. Tsang TK et al. Effects of infection history on dengue virus infection and pathogenicity. Nat Commun. 2019;10(1):1246. doi: 10.1038/s41467-019-09193-y.
15. Tricou V, Yu D, Reynales H, et al. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Glob Health. 2024; 12(2):e257-e270. doi: 10.1016/S2214-109X(23)00522-3.
16. FDA. Dengvaxia. 2022. https://www.fda.gov/vaccines-blood-biologics/dengvaxia
17. BPOM. Persetujuan Izin Edar Vaksin Dengue (Qdenga) untuk Usia 6–45 Tahun. 2022. https://www.pom.go.id/new/view/more/pers/659/Persetujuan-Izin-Edar-Vaksin-Dengue--Qdenga--untuk-Usia-6---45-Tahun.html
18. Jasamai M, Yap WB, Sakulpanich A, Jaleel A. Current prevention and potential treatment options for dengue infection. J Pharm Pharm Sci. 2019;22(1):440-456. doi: 10.18433/jpps30216.